Biopharma Contract Manufacturing
Biopharma Contract Manufacturing
Search
Words of Health and Hope
Click here to hear from our patients, who have expressed to us in beautifully written thank you notes for our BI Cares Patient Assistance Program.
Across Cancer Types
Across Cancer Types
Leadership insights about our focus on patient centricity
Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Heart Failure
Heart Failure
Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease
Data shows JARDIANCE reduced the risk for new-onset or worsening kidney disease in adults with T2D with established CV disease. View ISI, PI & Med Guide.
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
Lung Cancer
Lung Cancer
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Volunteering to Strengthen the Human-Animal Bond
Volunteering to Strengthen the Human-Animal Bond
Respiratory
Respiratory
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Fremont, CA site
Fremont, CA site
Ivermectin in Animal Health products and COVID-19
Ivermectin in Animal Health products and COVID-19
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
Clinical Pharmacology
Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.
Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad
Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad
Our Innovation Strategy
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Duluth, Georgia
Boehringer Ingelheim Animal Health employs about
Helping pets in hurricane-ravaged Puerto Rico
Helping pets in hurricane-ravaged Puerto Rico
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status